The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy). If it is approved by the European Commission it will be the first PD-1 immunotherapy treatment… Read More
Diana Turner counts down the biggest DDW news stories of 2025. 10. First use of CAR-T therapy to treat ulcerative colitis In October, a team of physicians at the German Center for Immunotherapy at Erlangen University Hospital succeeded for the first time in treating a 21-year-old female patient with therapy-resistant,… Read More
Dave Cole, Head of Research, Accession Therapeutics, introduces a replicating viral platform for systemic tumour targeting. Cancer immunotherapy has transformed oncology. Immune checkpoint inhibitors and cell therapies have shown that the immune system can be mobilised to achieve durable tumour control. Yet for most patients, response rates remain modest. Many… Read More
Citius Oncology has announced the US commercial launch of Lymphir, its novel cancer immunotherapy for cutaneous T-cell lymphoma (CTCL). The launch follows approval by the US Food and Drug Administration (FDA) in August 2024 for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL). The FDA approval was… Read More
Citius Oncology has partnered with technology company Verix to advance the commercial launch of its novel immunotherapy Lymphir. Lymphir is used for the treatment of adult patients with elapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. The treatment was previously approved by the US… Read More
Biotechnology company MaaT Pharma has announced preclinical results for its drug candidate MaaT034, including promising anti-tumour efficacy results and immune activation. MaaT034, a first-in-class co-cultured full ecosystem product, is designed to optimise intestinal microbiome functions and improve patient responses to immunotherapy in combination with Immune Checkpoint Inhibitors (ICIs). The… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, Galapagos announced plans to shelve its cell therapy business and hundreds of… Read More
News round-up for 20 – 24 October by Bruno Quinney, Content Team at DDW. This week’s leading story comes from biotech, with Galapagos announcing plans to shelve its cell therapy business and hundreds of employees set to lose theirjobs. Elsewhere, pharma firms are offering discounts to US… Read More
Scientists have identified a set of ‘signature’ genes that can determine the success of immune cells inside cancer tumours. Research published in Nature Communications reveals that scientists at the University of Tokyo, Japan identified whether CD8+ T cells, a type of immune cell, will multiply… Read More
A new AI model developed by Google and Yale researchers has revealed a potential novel cancer therapy pathway. The AI model ‘Cell2Sentence-Scale 27B’ analyses single-cell RNA data using large language models and is designed to be a bridge to make single-cell data accessible, or interpretable, by AI. Read More
A trio of French organisations across pharma, government and academia have partnered with the aim of accelerating immunotherapy for oncology, inflammation, and autoimmunity research. OSE Immunotherapeutics, Inserm Transfert and Nantes University have signed a strategic partnership which will combine academic research with industrial expertise to bring more immunotherapies… Read More
A team of physicians at the German Center for Immunotherapy at Erlangen University Hospital has succeeded for the first time worldwide in treating a 21-year-old female patient with therapy-resistant, severe chronic inflammatory bowel disease (ulcerative colitis) using cell therapy with CD19 CAR-T cells. The 21-year-old patient had… Read More
Biotechnology company Athernal Bio has announced its official launch, aiming to develop targeted immunotherapies for high-risk clonal haematopoiesis (CH). The launch follows funding worth £3.5 million ($4.7 million) from venture capital firm Delin Ventures. It is hoped that the financial backing can support preclinical milestones as Athernal Bio intends to… Read More
DDW Editor Reece Armstrong speaks to Dr Laura Aguilar, CMO of Diakonos Oncology, about the challenges of treating glioblastoma (GBM) and the approaches the company is taking to help tackle this devastating disease. RA: Why has GBM remained such a hard cancer to treat? LA: First, GBM, also known as… Read More
This is the latest episode of the free DDW narrated podcast, titled “Strategies and challenges in therapeutic development and lab practice”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “The inner workings of antibiotics”, “Targeting advances in immunotherapies”, and… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week has seen some incredible advances in immunotherapy, including the development of a therapy… Read More
